Market smells blood, gives CSL a whack
Shares in pharma giant CSL (ASX:CSL) took a hit yesterday after it revealed a larger than forecast loss from currency movements for its 2022-23 financial year. Instead of the impact – estimated earlier this year at the interim results, at around $US175 million, CSL told the ASX on Wednesday the figure was now more like […]
Market smells blood, gives CSL a whack Read More »

